In this issue of Blood, Ross et al report the TWISTER study in which imatinib was stopped in chronic myeloid leukemia patients with undetectable minimal residual disease (UMRD) and show that >40% remained off treatment without recurrence at 2 years.1 © 2013 by The American Society of Hematology.
CITATION STYLE
Apperley, J. F. (2013). TWIST it but don’t spin it. Blood, 122(4), 470–471. https://doi.org/10.1182/blood-2013-06-506097
Mendeley helps you to discover research relevant for your work.